Bli medlem
Bli medlem

Du är här

2016-12-19

Saniona AB: Saniona expects to report topline data for Tesomet in type 2 diabetes in early January

PRESS RELEASE

December 19, 2016

Saniona, a leading biotech company in the field of ion channels, today
announces that it expects to provide topline data in early January 2017 from
its Phase 2a study for Tesomet in patients with type 2 diabetes.

"The study has progressed as planned. This Phase 2a study was initiated on
April 20 and already by August 8 we could report that the last patient was
enrolled. The study comprises a total of 60 patients. We are pleased to
inform that 58 patients have completed the study successfully. We have now
locked the database and the independent statisticians will be analysing the
results during the next few weeks. Therefore, we expect to report topline
data prior to the JP Morgan conference on January 9-11, 2017, where the
entire healthcare industry is gathered. This is ideal timing for Saniona,"
says Jørgen Drejer, CEO at Saniona.

For more information, please contact

Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957,
E-mail:tf@saniona.com

This information is information that Saniona (publ) is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out above, at 08:00
CET on December 19, 2016.

About Saniona

Saniona is a research and development company focused on drugs for diseases of
the central nervous system, autoimmune diseases, metabolic diseases and
treatment of pain. The company has a significant portfolio of potential drug
candidates at pre-clinical and clinical stage. The research is focused on ion
channels, which makes up a unique protein class that enables and controls the
passage of charged ions across cell membranes. Saniona has ongoing
collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith
Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based
spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc.
Saniona is based in Copenhagen, Denmark, where it has a research center of
high international standard. Saniona is listed at Nasdaq First North Premier
and has about 4,600 shareholders. Pareto Securities is Certified Advisor for
Saniona. The company's share is traded under the ticker SANION. Read more at
www.saniona.com.

20161219 - PR - Tesomet Phase 2a update - UK
http://hugin.info/172499/R/2066176/775656.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Saniona AB via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.